The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper (Q26773027)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

review article

1 reference

title

The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

1

Neal A Halsey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

2

Kawsar R Talaat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

6

Tina Proveaux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Adena Greenbaum

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

Eric Mensah

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

Matthew Z Dudley

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

1 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

volume

33 Suppl 5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

F1-F67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

The burden of influenza in young children, 2004-2009.

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The science of evaluation of adverse events associated with vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

HIV vaccine development at the turn of the 21st century

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

An algorithm for treatment of patients with hypersensitivity reactions after vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

New technologies for influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Influenza vaccines: from whole virus preparations to recombinant protein technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval--a useful approach to pandemic vaccine development even in less well developed countries?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Development of pandemic influenza vaccine production capacity in Viet Nam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Adverse drug reactions of spontaneous reports in Shanghai pediatric population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Assessing the safety of influenza vaccination in specific populations: children and the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Biologically plausible and evidence-based risk intervals in immunization safety research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

An evidence based protocol for the prevention of upper arm injury related to vaccine administration (UAIRVA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Evaluating adverse events after vaccination in the Medicare population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Cellulitis and Myositis Caused by Agrobacterium radiobacter and Haemophilus parainfluenzae After Influenza Virus Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The predilection of chickenpox exanthema to influenza vaccine injection site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Global classification and coding of hypersensitivity diseases - An EAACI - WAO survey, strategic paper and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Management of anaphylaxis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

International consensus on (ICON) anaphylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

IgE and mast cells in allergic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Allergic reactions to vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Administering influenza vaccine to egg-allergic persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of latex allergy from medication vial closures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Ovalbumin content of 2010-2011 influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Adverse reactions to vaccines practice parameter 2012 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Vaccination-associated anaphylaxis in adults: diagnostic testing ruling out IgE-mediated vaccine allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Severe serum sickness after H1N1 influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Anaphylaxis: a review of causes and mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Oculorespiratory syndrome after influenza immunization in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Standard 4: determining adequate sample sizes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Diagnosis of Food Allergy: Epicutaneous Skin Tests, In Vitro Tests, and Oral Food Challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Events temporarily associated with anti-influenza A (H1N1) vaccination in Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Anaphylaxis following H1N1 pandemic vaccines: Safety data in perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Adverse events reported following live, cold-adapted, intranasal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Cutaneous vasculitis following influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Henoch-Schönlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Comparative trial of influenza vaccines. II. Adverse reactions in children and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Reactions and serologic responses in young children and infants after administration of inactivated monovalent influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Summary of Clinical Trials of Influenza Virus Vaccines in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of a paediatric presentation of an influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A Phase III Evaluation of Immunogenicity and Safety of Two Trivalent Inactivated Seasonal Influenza Vaccines in US Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Neurodiagnostic evaluation of the child with a simple febrile seizure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of intracranial pathologic conditions requiring emergency intervention after a first complex febrile seizure episode among children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Register-based studies on febrile seizures in Denmark

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Genetic background of febrile seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Vaccines and febrile seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Etiologies for seizures around the time of vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of the trivalent inactivated influenza vaccine among children: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Fever following administration of two inactivated influenza vaccines--a survey of parents of New Zealand infants and children 5 years of age and under

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: a comparison of published and unpublished studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Adverse events associated with 2010 CSL and other inactivated influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Febrile seizures after 2010–2011 influenza vaccine in young children, United States: A vaccine safety signal from the vaccine adverse event reporting system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Live attenuated versus inactivated influenza vaccine in infants and young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Frequency of adverse reactions after influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Side Effects Associated With Influenza Vaccination in Healthy Working Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Clinical signs and symptoms predicting influenza infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Inflammatory responses to trivalent influenza virus vaccine among pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Serum proinflammatory cytokine responses to influenza virus vaccine among women during pregnancy versus non-pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Juvenile idiopathic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The genetics of juvenile idiopathic arthritis: what is new in 2010?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Environmental factors and the geoepidemiology of juvenile idiopathic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Do infections trigger juvenile idiopathic arthritis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Onset of adult-onset Still’s disease following influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Shoulder injury related to vaccine administration (SIRVA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Magnetic resonance imaging of abnormal shoulder pain following influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A "needling" problem: shoulder injury related to vaccine administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Acute brachial neuritis following influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Atraumatic osteonecrosis of the humeral head after influenza A-(H1N1) v-2009 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Vaccine administration: preventing serious shoulder injuries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Subdeltoid/subacromial bursitis associated with influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barré syndrome: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The immunobiology of Guillain-Barré syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Campylobacter jejuni infection and Guillain-Barré syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Monitoring the safety of vaccines: assessing the risks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barré syndrome: the swine influenza virus vaccine incident in the United States of America, 1976-77: preliminary communication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barré syndrome in the US Army

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barré Syndrome After Influenza Vaccination in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

No evidence of a link between influenza vaccines and Guillain–Barre syndrome–associated antiganglioside antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barré Syndrome Following Influenza Vaccination: Causal or Coincidental?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Absence of P2 protein in swine flu vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Experimental neuritis induced by a mixture of neural antigens and influenza vaccines. A possible model for Guillain-Barré syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The Risk of Guillain–Barré Syndrome Associated with Influenza A (H1N1) 2009 Monovalent Vaccine and 2009–2010 Seasonal Influenza Vaccines: Results from Self‐Controlled Analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Tutorial in biostatistics: the self-controlled case series method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Neurologic complications of influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Acute disseminated encephalomyelitis: postinfectious, postimmunization and variant forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Post-vaccination encephalomyelitis: literature review and illustrative case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Acute disseminated encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Post-infectious encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Routine childhood vaccination against smallpox reconsidered

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Simultaneous development of acute disseminated encephalomyelitis and Guillain-Barré syndrome associated with H1N1 09 influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Influenza vaccine-induced CNS demyelination in a 50-year-old male

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004–2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Epstein-Barr virus and multiple sclerosis: interaction with HLA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Vaccinations and Risk of Central Nervous System Demyelinating Diseases in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Association of infectious mononucleosis with multiple sclerosis. A population-based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk factors of multiple sclerosis: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The impact of influenza vaccinations on the adverse effects and hospitalization rate in the elderly: a national based study in an Asian country

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunizations and risk of multiple sclerosis: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Influenza virus vaccination of patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Swine Influenza Virus Vaccination in Patients with Multiple Sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Swine Influenza Vaccination in Patients With Multiple Sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Seasonal and H1N1v influenza vaccines in MS: Safety and compliance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The adjuvant component α-tocopherol triggers via modulation of Nrf2 the expression and turnover of hypocretin in vitro and its implication to the development of narcolepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The roles of influenza virus antigens and the AS03 adjuvant in the 2009 pandemic vaccine associated with narcolepsy needs further investigation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Evaluating the safety of influenza vaccine using a claims-based health system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Sleepiness that cannot be overcome: Narcolepsy and cataplexy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

CD4 T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Selective retrograde transsynaptic transfer of a protein, tetanus toxin, subsequent to its retrograde axonal transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Bell's palsy associated with influenza vaccination: two case reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Neurological complications after H1N1 influenza vaccination: magnetic resonance imaging findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Diagnosis and management of autoimmune cytopenias in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A case of immune thrombocytopenic purpura after influenza vaccination: consequence or coincidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Effect of Live Measles Vaccine on the Platelet Count

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Relapse of idiopathic thrombocytopenic purpura caused by influenza A virus infection: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Recurrent idiopathic thrombotic thrombocytopenic purpura: a role for vaccination in disease relapse?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A case-control study to assess the risk of immune thrombocytopenia associated with vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Epidemiology of virus-induced wheezing/asthma in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Clinical and epidemiologic factors related to subsequent wheezing after virus-induced lower respiratory tract infections in hospitalized pediatric patients younger than 3 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Ion flux in the lung: virus-induced inflammasome activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Atopy history and the genomics of wheezing after influenza vaccination in children 6-59 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety of live-attenuated influenza vaccination in cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987/88

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac (®) ) in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A randomized, controlled trial in children to assess the immunogenicity and safety of a thimerosal-free trivalent seasonal influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The spectrum of post-vaccination inflammatory CNS demyelinating syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Common viruses associated with lower pediatric multiple sclerosis risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Intranasal Influenza Vaccine in a Working Population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Bell's palsy and parenteral inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

An adverse event following 2009 H1N1 influenza vaccination: a case of acute disseminated encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

MMR vaccine and idiopathic thrombocytopaenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Idiopathic thrombocytopenic purpura and MMR vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Vaccination associated thrombocytopenic purpura in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

Patients who develop inflammatory polyarthritis (IP) after immunization are clinically indistinguishable from other patients with IP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.10.080

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.10.080

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822822 AND SRC:MED&resulttype=core&format=json

6 March 2020

1 reference